TerminatedNot applicableNCT02168036

Study of Biologic Materials From the Mediastinal Lymph Nodes From Patients With Lung Disease.

The purpose of this protocol is to obtain biologic materials from the mediastinal lymph nodes from patients with lung disease and mediastinal lymph node involvement in order to: (1) develop a better understanding of the cause and development of lung disorders involving the mediastinal lymph nodes; (2) identify biologic parameters that help diagnose and predict the behavior of human lung diseases; and (3) identify individuals who will be suitable candidates for other protocols such as those involving investigational new drugs.

Checked against the public recordLast updated Dec 26, 2017 · Source: ClinicalTrials.gov

StatusTerminated
PhaseNot applicable
U.S. locations1
SponsorWeill Medical College of Cornell University
01
Study overview

What this study is about

Purpose
Not specified
Study type
Observational
Phase
Not applicable
Sponsor
Weill Medical College of Cornell University
Interventions being studied
Not specified
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

03
Public criteria

Who may be able to participate

Inclusion Criteria: * Must provide informed consent * Males and females, age 18 years and older * Lung disease proven by at least one of the following: 1. symptoms consistent with pulmonary disease 2. chest X-ray and chest CT and/or PET CT scan consistent with lung disease and mediastinal lymph node involvement 3. lung biopsy consistent with lung disease known to involve mediastinal lymph nodes 4. patients with diseases of organs with known association to lung disease and mediastinal lymph node involvement. * Undergoing fiberoptic bronchoscopy with EBUS-TBNA as dictated by their standard clinical care Exclusion Criteria: * Patient refuses consent. * Any history of allergies to xylocaine, lidocaine, versed, valium, atropine, or any local anesthetic will not be included in the study * Individuals who cannot tolerate general anesthesia or moderate sedation and analgesia

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Weill Cornell Medical College and Weill Cornell Medical Center, Department of Genetic MedicineNew York, New York

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Dec 26, 2017. Always confirm current availability with the study team.

View original record ↗